LLGL1 Activators
LLGL1 Activators encompass a range of chemical compounds that indirectly augment the functional activity of LLGL1 through various signaling pathways, particularly those governing cell polarity and cytoskeletal organization. PKC activators, such as Phorbol 12-myristate 13-acetate (PMA) and 1,2-Dioctanoyl-sn-glycerol (DiC8), enhance the phosphorylation state of proteins within cell polarity pathways, likely increasing LLGL1's interaction with those proteins and its subsequent activity in maintaining cellular architecture. Forskolin, by raising cAMP levelsand thereby activating PKA, indirectly promotes LLGL1's role in cell adhesion and polarity by influencing protein localization and stability. Similarly, dibutyryl-cAMP (db-cAMP), as a cAMP analog, activates PKA, which may augment LLGL1's activity by phospho-regulating proteins involved in cell polarity. EGF, through its receptor-mediated signaling, activates PI3K and AKT signaling, potentially enhancing LLGL1's involvement in cell migration and polarity due to downstream effects on the cell's structural dynamics.
Moreover, the use of specific inhibitors like Gö 6983, Bisindolylmaleimide I (BIM I), Ro-31-8220, and Staurosporine shifts the kinase activity within the cell, which can indirectly lead to an enhanced functional state of LLGL1 by modulating its associations within cell polarity complexes. The perturbation of kinase activity can selectively influence LLGL1's interactions, resulting in its increased activity in establishing cell polarity. U73122 and Calyculin A, by modulating phospholipase C activity and inhibiting protein phosphatases, respectively, can also impact the phosphorylation landscape of proteins that associate with LLGL1, potentially leading to an upregulation of LLGL1 activity. NSC 23766, which inhibits Rac1, could induce compensatory cellular responses that enhance LLGL1's role in cytoskeletal dynamics and cell polarity, exemplifying how the modulation of small GTPase signaling pathways can indirectly affect LLGL1 function. Collectively, these LLGL1 Activators, through targeted effects on cellular signaling, facilitate the enhancement of LLGL1-mediated functions critical for maintaining cell architecture without directly upregulating its expression or binding.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
As a diacylglycerol analog, PMA directly activates protein kinase C (PKC), which can then phosphorylate and regulate various substrates involved in cytoskeletal organization and cell polarity, pathways where LLGL1 plays a crucial role. This phosphorylation cascade may enhance the functional activity of LLGL1 by modulating its interactions with other cell polarity proteins. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
As an inhibitor of protein phosphatases 1 and 2A, Calyculin A prevents dephosphorylation of proteins, potentially leading to enhanced phosphorylation states of proteins within cell polarity pathways that could augment LLGL1 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983 is a potent PKC inhibitor that can reduce PKC activity. By modulating PKC signaling, it might influence the state of proteins that interact with LLGL1, potentially enhancing LLGL1's role in cell polarity and architecture. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
BIM I is another PKC inhibitor. By inhibiting certain PKC isoforms, it could shift the balance of cell polarity signaling, leading to an enhanced functional state of LLGL1 in its role in this cellular process. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cAMP analog that activates PKA, leading to phosphorylation of components in cell polarity and adhesion pathways. This could indirectly increase LLGL1's activity by modulating these pathways. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220 is a PKC inhibitor with a broad spectrum. By modulating PKC-mediated signaling, it may affect LLGL1's interactions and functions within cell polarity complexes, potentially enhancing LLGL1's activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. By inhibiting specific kinases, it could selectively alter the signaling pathways that LLGL1 is a part of, potentially leading to enhanced LLGL1 activity in cell polarity and architecture. | ||||||